Stay updated on Faricimab in Neovascular AMD Clinical Trial
Sign up to get notified when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.

Latest updates to the Faricimab in Neovascular AMD Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe page’s release/version label was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” indicating a change to the website build or documentation skin rather than the underlying clinical trial content.SummaryDifference0.0%

- Check16 days agoChange DetectedAdded Revision: v3.5.2; Deleted Revision: v3.5.0.SummaryDifference0.0%

- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedPublications section updated with a new 2026 JAMA Ophthalmol. article and removal of the previously listed online-ahead-of-print version.SummaryDifference0.0%

- Check44 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check66 days agoChange Detected- Added Publication citation: Pitcher JD 3rd, Koh AHC, Tan CS, Vakharia P, Dagincourt N, Patel S, Yang M, Margaron P, Gallego-Pinazo R. Rapid Fluid Resolution and Durability With Faricimab in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2026 Feb 19:e256365. Online ahead of print.SummaryDifference0.0%

Stay in the know with updates to Faricimab in Neovascular AMD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Faricimab in Neovascular AMD Clinical Trial page.